Evidence map›Paper›PMID 42538585›Full record

ArticlePharmacology research & perspectives2026

Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB-9778.

Lina El Badaoui, Stipo Jurcevic, Yotis A Senis, Alastair J Barr

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lina El BadaouiSchool of Life Sciences, University of Westminster, London, UK.ORCID https://orcid.org/0000-0002-4404-2021
Stipo JurcevicSchool of Life Sciences, University of Westminster, London, UK.ORCID https://orcid.org/0009-0001-4274-4070
Yotis A SenisCentre for Cardiovascular and Nutrition Research, INSERM 1263, INRAE 1260, Faculty of Medicine, Aix-Marseille University, Marseille, France.ORCID https://orcid.org/0000-0002-0947-9957
Alastair J BarrSchool of Life Sciences, University of Westminster, London, UK.ORCID https://orcid.org/0000-0001-7738-8419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD148 is the primary receptor-type protein tyrosine phosphatase (PTP) regulating platelet activation, and its inhibition has been proposed as a novel anti-thrombotic strategy with potentially lower bleeding risk than current therapies. However, selective and potent inhibitors of CD148 are currently lacking. AKB-9778 (razuprotafib), a potent inhibitor of the closely related vascular endothelial-PTP (VE-PTP), has also been reported to inhibit CD148. This study investigated the effect of AKB-9778 on in vitro whole-blood thrombogenicity, examined the molecular basis of its interaction with the CD148 catalytic domain using molecular docking, and assessed inhibitor selectivity with an in vitro phosphatase assay. In a total-thrombus formation analysis system (T-TAS), AKB-9778 partially inhibited thrombus formation, reducing AUC

Indexed as

Fibrinolytic AgentsReceptor-Like Protein Tyrosine Phosphatases, Class 3ThrombosisAnimalsBlood PlateletsCatalytic DomainHumansMolecular Docking SimulationPlatelet ActivationFibrinolytic AgentsReceptor-Like Protein Tyrosine Phosphatases, Class 3AKB‐9778CD148molecular dockingplateletsPTPRJrazuprotafibreceptor‐type protein tyrosine phosphatasethrombosisT‐TASVE‐PTP

Identifiers

PMID42538585
PMCPMC13428021

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.